RLFTY (MindMaze Therapeutics Holding) ROIC %: -46.34% (As of Dec. 2025)


RLFTY MindMaze Therapeutics Holding SA RLFTY
11 GF Score
Price $0.42
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding ROIC %?

MindMaze Therapeutics Holding RLFTY 11 ROIC % is -46.34% as of Dec. 2025. GuruFocus rates RLFTY with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. MindMaze Therapeutics Holding's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2025 was -46.34%.

As of today (2026-07-02), MindMaze Therapeutics Holding's WACC % is 6.86%. MindMaze Therapeutics Holding's ROIC % is -46.33% (calculated using TTM income statement data). MindMaze Therapeutics Holding earns returns that do not match up to its cost of capital. It will destroy value as it grows.

MindMaze Therapeutics Holding  (OTCPK:RLFTY) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, MindMaze Therapeutics Holding's WACC % is 6.86%. MindMaze Therapeutics Holding's ROIC % is -46.33% (calculated using TTM income statement data). MindMaze Therapeutics Holding earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

MindMaze Therapeutics Holding ROIC % Related Terms

MindMaze Therapeutics Holding ROIC % Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding ROIC % Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
ROIC %
-1.92 -46.34

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
ROIC % -1.92 -46.34

RLFTY vs VRTX, REGN, ALNY: ROIC % Comparison

For the Biotechnology subindustry, MindMaze Therapeutics Holding's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindMaze Therapeutics Holding ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's ROIC % distribution charts can be found below:

* The bar in red indicates where MindMaze Therapeutics Holding's ROIC % falls into.


RLFTY
11GF Score
MindMaze Therapeutics Holding SA RLFTY
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding ROIC % Calculation

MindMaze Therapeutics Holding's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-13.195 * ( 1 - 0% )/( (0.104 + 56.839)/ 2 )
=-13.195/28.4715
=-46.34 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.104 - 0.002 - ( 0 - max(0, 0.002 - 0+0))
=0.104

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=64.663 - 5.04 - ( 11.887 - max(0, 13.716 - 16.5+11.887))
=56.839

MindMaze Therapeutics Holding's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2025 is calculated as:

ROIC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-13.195 * ( 1 - 0% )/( (0.104 + 56.839)/ 2 )
=-13.195/28.4715
=-46.34 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.104 - 0.002 - ( 0 - max(0, 0.002 - 0+0))
=0.104

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=64.663 - 5.04 - ( 11.887 - max(0, 13.716 - 16.5+11.887))
=56.839

Note: The Operating Income data used here is one times the annual (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -46.34% mean?
MindMaze Therapeutics Holding (RLFTY) has a ROIC % of -46.34% as of Dec. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's ROIC % too high?
MindMaze Therapeutics Holding's current ROIC % is -46.34%. Overall, MindMaze Therapeutics Holding has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's ROIC % compare to VRTX and REGN?
MindMaze Therapeutics Holding's ROIC % of -46.34% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current ROIC % is -46.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (RLFTY) has a current ROIC % of -46.34%. The current ROIC % is -46.34%. MindMaze Therapeutics Holding's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For MindMaze Therapeutics Holding (RLFTY), the current ROIC % is -46.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges MMTXz:UKMMTX:Switzerland
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
11GF Score

Get the complete analysis for RLFTY

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price